Emixustat HCl
Stargardt Disease
Key Facts
About Kubota Vision
Kubota Vision is a clinical-stage biotech focused on ophthalmic diseases, advancing a hybrid pipeline of small molecule therapeutics and novel medical devices. Its lead asset is emixustat HCl, in development for Stargardt disease and proliferative diabetic retinopathy, while its device portfolio includes the Kubota Glass for myopia control and remote retinal monitoring systems. The company leverages its position within the Kubota Pharma Group to pursue a dual strategy of treating retinal diseases and managing common refractive errors with high-tech solutions.
View full company profileAbout Kubota Vision
Kubota Vision is a clinical-stage biotech focused on ophthalmic diseases, advancing a hybrid pipeline of small molecule therapeutics and novel medical devices. Its lead asset is emixustat HCl, in development for Stargardt disease and proliferative diabetic retinopathy, while its device portfolio includes the Kubota Glass for myopia control and remote retinal monitoring systems. The company leverages its position within the Kubota Pharma Group to pursue a dual strategy of treating retinal diseases and managing common refractive errors with high-tech solutions.
View full company profileTherapeutic Areas
Other Stargardt Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| KIO-301 | Kiora Pharmaceuticals | Preclinical |
| EIR-0205 | EIR Biopharma | Preclinical |
| Gildeuretinol (ALK-001) | Alkeus Pharmaceuticals | Phase 3 |
| MCO-010 | Nanoscope Therapeutics | Phase 2 |
| SB-007 | SpliceBio | Phase 1/2 |
| LBS-008 | Lin BioScience | Phase 3 |
| OCU410ST | Ocugen | Phase 2/3 |
| ABO-504 | Abeona Therapeutics | Preclinical |